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Abstract
Background: Cancer stem cells (CSCs) play an important role in the development and recurrence of malignant
tumors including glioma. Notch signaling, an evolutionarily conserved pathway mediating direct cell-cell
interaction, has been shown to regulate neural stem cells (NSCs) and glioma stem cells (GSCs) in normal
neurogenesis and pathological carcinogenesis, respectively. However, how Notch signaling regulates the
proliferation and differentiation of GSCs has not been well elucidated.
Methods: We isolated and cultivate human GSCs from glioma patient specimens. Then on parallel comparison
with NSCs, we inhibited Notch signaling using g-secretase inhibitors (GSI) and assessed the potential functions of
Notch signaling in human GSCs.
Results: Similar to the GSI-treated NSCs, the number of the primary and secondary tumor spheres from GSI-treated
GSCs decreased significantly, suggesting that the proliferation and self-renewal ability of GSI-treated GSCs were
attenuated. GSI-treated GSCs showed increased differentiation into mature neural cell types in differentiation
medium, similar to GSI-treated NSCs. Next, we found that GSI-treated tumor spheres were composed of more
intermediate progenitors instead of CSCs, compared with the controls. Interestingly, although inhibition of Notch
signaling decreased the ratio of proliferating NSCs in long term culture, we found that the ratio of G2+M
phase-GSCs were almost undisturbed on GSI treatment within 72 h.
Conclusions: These data indicate that like NSCs, Notch signaling maintains the patient-derived GSCs by promoting
their self-renewal and inhibiting their differentiation, and support that Notch signal inhibitor GSI might be a
prosperous candidate of the treatment targeting CSCs for gliomas, however, with GSI-resistance at the early stage
of GSCs cell cycle.
Background
Glioma, the most common tumor of the central nervous
system (CNS), frequently leads to death. Glioma is
derived from brain glial tissue and comprises several
diverse tumor forms and grades. Treatment of malig-
nant gliomas is often palliative due to their infiltrating
nature and high recurrence. Despite advances in surgery,
chemotherapy and radiation gradually result in therapy-
resistance. However, genetic events that lead to gliomas
are mostly unknown.
Recent researches highlight the importance of cancer-
initiating cells in the malignancy of gliomas [1-3]. These
cells have been referred to as glioma stem cells (GSC),
as they share similarities to normal neural stem cells
(NSCs) in the brain. There is increasing evidence that
malignant gliomas arise from and contain these minority
tumor cells with stem cell-like properties. This subpopu-
lation of tumor cells with the potential for self-renewal
and multi-lineage differentiation that recapitulates the
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tant role in glioma initiation, growth, and recurrence.
Eliminating GSCs from the bulk tumor mass seems to
be a prosperous therapeutic strategy [9,10]. Therefore, it
is extremely important to understand the signal path-
ways that contribute to the formation and maintenance
of GSCs.
A number of signal pathways are involved in the for-
mation and maintenance of stem cells, many of which
are closely conserved across species. Notch signaling, an
evolutionarily conserved pathway mediating direct cell-
cell interaction and signaling, plays a pivotal role in the
maintenance of NSCs [11]. The functions of the Notch
pathway in cancer formation have been gradually estab-
lished, and recent data have also implicated a role for
Notch signaling in GSCs [12]. Notch is a family of het-
ero-dimeric transmembrane receptors composed of an
extracellular domain responsible for ligand recognition,
a transmembrane domain, and an intracellular domain
involved in transcriptional regulation. When Notch
receptor is triggered by the ligands on the neighboring
cells, the intracellular domain of the Notch receptor
(NICD) is released from the membrane, after successive
proteolytic cleavages by the g-secretase complex [13,14].
NICD then translocates into the nucleus and associates
with the transcription factor RBP-J, the DNA recombi-
nation signal binding protein-J. The NICD-RBP-J com-
plex further recruits other co-activators, and activates
the expression of downstream genes associated with cell
proliferation, differentiation and apoptosis [15]. It is
believed that g-secretase inhibitors (GSI) decrease the
activity of Notch signaling and slow the growth of
Notch-dependent tumors such as medulloblastoma [12].
Rapid proliferation, self-renewal ability and multipo-
tential differentiation are the hallmarks of both normal
NSCs and GSCs. Similarities in the growth characteris-
tics and gene expression patterns of normal NSCs and
brain tumor CSCs suggest that pathways important for
NSCs are probable targets for eliminating brain tumor
CSCs. The RBP-J-mediated canonical Notch pathway
plays several significant roles in the maintenance and
differentiation of NSCs [16-18]. During embryogenesis,
Notch signaling is required to maintain all NSC popula-
tions, and to repress the differentiation of NSCs into
intermediate neural progenitors (INPs) in vivo [19-21].
Along with later development, Notch signal commits
NSCs to an astroglia fate, while repressing neuronal dif-
ferentiation [22]. In adult, Notch signaling modulates
cell cycle in order to ensure brain-derived NSCs retain
their self-renewal property [23].
Increasing evidence has shown that there is a link
between tumorigenesis and aberrantly activated Notch
signaling [24,25]. Notch1 and its ligands, Dll1 and
Jagged1, were overexpressed in many glioma cell lines
and primary human gliomas. When the expression of
Notch1, Dll1 or Jagged1 was down-regulated by RNA
interference, apoptosis and proliferation inhibition in
multiple glioma cell lines were induced [26]. Depletion
of Hey1, a member of Hes-related family downstream
effectors of Notch signaling, by RNA interference also
reduces proliferation of glioblastoma cells in tissue cul-
ture [27]. Moreover, the blockade of Notch signaling
directly caused cell cycle exit, apoptosis, differentiation,
and reduced the CD133-positive cells in medulloblas-
toma and glioblastoma cell lines while Notch activation
enhances the expression of Nestin, promotes cell prolif-
eration and the formation of NSC-like colonies and
plays a contributing role in the brain tumor stem cells
[28-30]. However, the exact roles of Notch signaling in
the proliferation and differentiation of patient-derived
GSCs have not been clearly elucidated.
In this study, we explore the roles of Notch signaling
in patient-derived GSCs with parallel analysis of normal
NSCs by using GSI-mediated inhibition of Notch signal-
ing in vitro. The results showed that when Notch signal-
ing was inhibited, the proliferation and self-renewal
ability of GSCs from human primary gliomas were atte-
nuated. In addition, the blockade of Notch signaling in
GSCs increased their differentiation into the down-
stream neural cell types, and promoted their conversion
from stem cells into INP-like cells. Interestingly,
although inhibition of Notch signaling definitely
decreased the proliferating GSCs in long term culture,
we found that the percentage of G2+M phase-GSCs
were almost undisturbed at the initial stage of GSI treat-
ment. To summarize, our results suggested that Notch
signaling maintained GSCs by promoting their self-
renewal and inhibiting their differentiation into INP-like
cells, and supported that Notch signal inhibitors might
be prosperous candidates of the treatments targeting
CSCs for gliomas.
Methods
Glioma samples
Glioma tissues were obtained from 9 adult patients with
pathologically diagnosed grade 2 to grade 4 gliomas, at
the Department of Neurosurgery in Xijing Hospital,
Fourth Military Medical University, under the guidance
from the Medical Ethnic Committee of the Fourth Mili-
tary Medical University. The summary of the patient
population is outlined in Additional file 1: Table S1.
Neurosphere culture
Neurosphere cultures were performed as described pre-
viously with some modifications [21]. Briefly, for the
culture of NSCs, the brains from embryonic (E) day 12.5
C57BL/6 mice were dissected under a stereomicroscope.
And for the culture of GSCs, tissues from patient
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sues were then washed, mechanically dissociated by
repetitive pipette. Single cells were primarily plated in
serum-free Dulbecco’s modified Eagle’sm e d i u m
(DMEDM)/F12 medium containing 20 ng/ml basic
fibroblast growth factor (bFGF, human recombinant,
Sigma), 20 ng/ml epidermal growth factor (EGF, mouse
submaxillary), the B-27 (1:50, GIBCO), penicillin (100
U/ml) and streptomycin (0.1 mg/ml). Cells were cul-
tured at a density of 1 × 10
5 cell/ml in 24-well plates
(0.5 ml/well), and were fed every 3 days by adding fresh
medium supplemented with GSI or DMSO with
indicated concentrations. Animal experiments were
reviewed and approved by the Animal Experiment
Administration Committee of the Fourth Military Medi-
cal University.
Neurosphere assays
After 7 days from primary culture the numbers of pri-
mary spheres were counted under a microscope (Addi-
tional file 1: Figure S2) [21]. And for the expression of
target genes, neurospheres were harvested on the 5th
day of culture for RNA extraction, cDNA synthesis, and
real-time reverse transcription-polymerase chain reac-
tion (RT-PCR). Primary neurospheres were harvested
and dissociated mechanically into single cell suspen-
s i o n s ,a n dw e r er e p l a t e da t1×1 0
5 cells/ml in 24-well
plates. Cells were then cultured for another 7 days until
secondary spheres formed [31], which were quantified
by counting. On the 7th day of primary culture, neuro-
spheres were plated onto poly-D-lysine (Sigma) coated
glass cover slips in DMEM/F12 containing 10% fetal
bovine serum (FBS) for another 7 days. On the third
day of differentiation, neurospheres were photomicro-
graphed and their neurites were counted and measured,
then on the 7th day of differentiation culture, immuno-
fluorescence staining was performed as described below.
Immunofluorescence
Undifferentiated neurospheres were plated onto poly-D-
lysine coated glass cover slips in serum-free medium for
4 h. Then cells were directly fixed in 4% paraformalde-
hyde at 4°C for 10 min, and incubated with primary
antibodies overnight at 4°C, followed by species-specific
secondary antibodies. Samples were visualized under
fluorescence microscope (FV-1000, Olympus, Japan).
Immunofluorescence for differentiated neurospheres was
performed in a similar way. Cells were additionally
counterstained with Hoechst. Primary antibodies used
included rabbit anti-Nestin serum (1:200, Sigma), rabbit
anti-glial fibrillary acidic protein (GFAP, 1:200, Sigma),
mouse anti-mitogen-activated protein 2 (MAP2, 1:200,
Sigma). FITC-conjugated goat anti-mouse IgG and Cy3-
conjugated goat anti-rabbit IgG (1:400, Jackson Immu-
noResearch) were used as the secondary antibodies.
Quantitative RT-PCR
Total RNA of neurospheres was isolated using the Tri-
zol reagent (Invitrogen). cDNA was synthesized and was
used for real-time PCR with a kit (SYBR Premix EX
Taq, Takara, Kyoto, Japan) and the ABI PRISM 7300
real-time PCR system, with human GAPDH and mouse
b-actin as the reference controls. Primers used for real-
time PCR were summarized in Additional file 1: Table
S3.
DNA content analysis
Spheres were dissociated mechanically into single cell
suspensions in the culture medium. Cells were then
washed and resuspended in PBS, and were fixed with
ethanol at room temperature for 20 min. Cells were
resuspended in PBS containing 50 μg/ml of propidium
iodide and 0.1 mg/ml RNase A for 10 min, and were
analyzed for ploidy using a flow cytometry (BD Bios-
ciences). Data analysis was performed using the Cell-
Quest software (BD Biosciences).
Statistics
Independent cultures from at least three samples were
used for each experiment (Additional file 1: Table S2).
For immunofluorescence, cells were counted by Image-
ProPlus 6.0, and only cell bodies that were labeled with
immunoreactivity were included. Proportions of immu-
noreactive cells in the total population of cultured cells
revealed by Hoechst staining were calculated, and at
least 5 microscopic fields per specimen were selected.
For neurite analysis, neurites of 30 neurospheres from
each culture in the presence of GSI or DMSO were
measured. The total numbers of neurites per tumor
spheres were counted via photomicrographs taken by a
phase contrast microscopy, and the average of the
length of neuritis per tumor spheres were measured by
Image-ProPlus 6.0. Each experiment was repeated for at
least three times. Data were expressed as mean ± s.e.m,
and the difference between the two groups was analyzed
with the Student’s t-test, with P < 0.05 as statistically
significant.
Results
Formation of neurosphere-like colonies from primary
glioma specimens
Nine specimens of gliomas were used in the current
studies, including 3 oligoastrocytomas, 3 oligodendro-
gliomas, 2 astrocytomas, and 1 glioblastoma, and the
specimens were graded according to the WHO grading
scheme (Additional file 1: Table S1).
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single cell suspension and were cultured in serum-free
DMEM/F12 medium supplemented with EGF and
bFGF. Seven primary gliomas of the nine gave rise to
proliferating tumor spheres. Regardless of pathological
subtype and grade, neurosphere-like clusters, or tumor
spheres, first appeared within 72 h of primary culture
and increased their numbers and diameters quickly dur-
ing 7 days after the onset of the culture (Figure 1A). In
order to estimate whether these tumor spheres showed
NSC properties, we stained the tumor spheres from
patients with anti-Nestin antibody. The result showed
that these tumor spheres expressed Nestin, a marker of
NSCs (Figure 1B). The multipotency of these human
glioma cell-derived tumor spheres was confirmed by dif-
ferentiation assay in vitro. We estimated the differentia-
tion capacity of tumor spheres in differentiating
conditions by examining the types of molecular markers
expressed by neurons and glial cells. We observed that
these cells could differentiate into GFAP-positive astro-
cyte- and MAP2-positive neuron-like cells (Figure 1C,
1D). In addition, a local recurrence tumor also could
produce tumor spheres in growth medium (data not
shown). Tumor spheres could be passed at least for five
generations by mechanical dissociation and their stem-
ness and multipotency could be maintained in serum-
free medium supplemented with growth factors for at
least one month.
Blockade of Notch signaling attenuates the proliferation
and self-renewal ability and promotes differentiation of
normal NSCs
Stem cell-like cells in brain tumors share many similari-
ties with normal neural stem/progenitor cells and may
Figure 1 Patient glioma-derived stem cells have the ability to form neurosphere-like colonies and gave rise to the downstream neural
cell types of NSCs. (A) Photomicrographs of typical primary tumor spheres from one glioma tissue at 72 h after plating. (B) Undifferentiated
primary tumor spheres expressed high levels of Nestin (red), a marker of NSCs. (C, D) The tumor spheres-derived from human glioma were
cultured in differentiation conditional medium for 7 days, and differentiated into neural cells expressing specific molecular markers of GFAP (C,
red) and MAP2 (D, green). Scale bar, 100 μm in A, and 50 μm in BCD.
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Page 4 of 13Figure 2 Blockade of Notch signaling attenuates proliferation and self-renewal ability of normal mouse NSCs. (A) Photomicrographs of
neurospheres derived from E12.5 mouse brain at 72 h after primary culture, with GSI or DMSO supplemented. (B, C) Total RNA was prepared
from neurospheres on the 5th day of GSI or DMSO treatment. And the expressions of Hes1 and Hes5 were measured by RT-PCR (B) and Real-
time PCR (C), with b-actin as the reference control (n = 3, Hes5, P = 0.006, Hes1, P = 0.006). (D, E) Equal number of cells (1 × 10
5/ml) were
plated in the growth medium, and the number of primary (n = 3, P = 0.010) (D) and secondary (n = 3, P = 0.043) (E) neurospheres were
counted 7 days after plating. *, P < 0.05, **, P < 0.01.
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vitro, NSCs proliferate and form clonal spheres referred
to as neurospheres. GSI reduced the proliferation of
mouse embryonic brain-derived NSCs in a dose-depen-
dent fashion (Additional file 1: Figure S1). The number
of neurospheres was decreased in the presence of
GSI, compared with the control treated with DMSO
(Figure 2A). In order to confirm that GSI effectively
blocked Notch signaling in NSCs in our culture system,
we test the expression of Hes1 and Hes5, both of which
are downstream molecules of the Notch signaling [12].
Total RNA was prepared from neurospheres on the fifth
day of 25 μmol/L GSI treatment and was used for RT-
PCR. The expression of Hes1 and Hes5 decreased
remarkably in NSCs, suggesting that GSI at this concen-
tration could inhibit Notch signaling effectively (Figure
2B, 2C). We quantitatively analyzed the number of pri-
mary neurospheres in the presence of GSI, and found
that there was a significant decrease in the number of
neurospheres upon GSI treatment at 25 μmol/L (Figure
2D). In order to determine the possible effect of GSI on
the NSCs self-renewal ability, we harvested the spheres
and dissociated them into a single cell suspension by
soft pipeting. When replated in the presence of GSI, the
number of secondary neurospheres significantly
decreased after 7 days culture (Figure 2E). These results
suggested that the proliferation of NSCs was slowed by
inhibiting Notch signaling and the self-renewal ability, a
key NSC behavior, was at least partially depleted.
Notch signaling has been shown to inhibit the differ-
entiation of NSCs to INPs [21]. In our study, we tested
the expression of molecular markers of INPs in primary
neurospheres treated with GSI or DMSO. Quantitative
RT-PCR showed that the mRNA levels of Glast, which
is indicative of the frequency of NSCs, were decreased,
while that of Mash1 and Tubulin a1, both of which are
markers of INPs, were increased (Figure 3A, 3B). These
results indicated an augmented differentiation from
NSCs into INPs upon the blockade of Notch signaling
by GSI.
To further study the effect of inhibiting Notch signal-
ing on NSC differentiation, we used the neurosphere
differentiation assay in vitro. When spheres were cul-
tured adherently on poly-D-lysine coated glass cover
slips without growth factors, they began to differentiate
into cells bearing specific markers of neurons and astro-
cytes. We quantitatively compared the cell types pro-
duced by neurospheres in the GSI-containing medium
with that of the control. All of the neurospheres gave
rise to cells with the molecular markers of neurons or
astrocytes (Figure 3C, 3D). However, the percentage of
MAP2
+ cells increased significantly in the presence of
GSI, from 29.0 ± 10.4% to 66.5 ± 8.4%, and the percen-
tage of GFAP
+ cells in GSI-treated neurospheres was
elevated from 8.7 ± 3.0% to 26.9 ± 6.6% (Figure 3E, 3F).
These results suggested that inhibiting Notch signaling
in NSCs leads to an increase in the number of differen-
tiated cells.
Decreased proliferation and self-renewal ability of GSCs
upon GSI treatment
Although Notch signaling has been shown to play criti-
cal roles in the maintenance of normal NSCs, whether
this signaling might be involved in tumor stem cells is
not fully clear. To determine whether Notch signaling
activity was required during growth of GSCs, we investi-
gate the effect of GSI on proliferation and self-renewal
of GSCs. After Notch signaling was inhibited in GSCs
by GSI treatment at 25 μmol/L, the expressions of Hes5
and Hes1, the specific and direct downstream targets of
the Notch/RBP-J transcription complex were identified
by RT-PCR and real-time PCR as described previously.
After 5 days of GSI treatment, Hes5 and Hes1 expres-
sion markedly decreased (Figure 4A, 4B), and no
obvious cell death was observed, indicating no effect on
cell viability (data not shown). These results indicated
that Notch signaling was efficiently blocked by GSI
treatment in GSCs.
Next, we quantitatively compared the proliferation and
self-renewal ability of GSI-treated GSCs with that of the
controls. The number of the primary tumor spheres in
the presence of GSI decreased significantly, from 51.5 ±
2.8 to 34.8 ± 3.3 (Figure 4C). Self-renewal ability of the
tumor spheres was assayed by dissociating and replating
the primary tumor spheres. Our results showed that
GSI-treated GSCs generated a decreased number of sec-
ondary tumor spheres (17.5 ± 2.3), than the number of
controls (31.7 ± 5.6) (Figure 4D). These results showed
that the proliferation and self-renewal ability of GSCs
also could be attenuated by inhibiting Notch signaling.
Blockade of Notch signaling promotes the differentiation
of GSCs
The previous result indicated that inhibiting Notch sig-
naling promotes the normal NSCs to differentiate into
neurons and astrocytes, both of which are the down-
stream neural cell types of NSCs. Therefore, we investi-
gated whether the GSI treatment promoted GSCs
differentiation. Interestingly, after 3 days, approximately
18.7 ± 0.9 neurites grew out from each tumor spheres
cultured in the medium with GSI, compared to only 6.7
± 0.9 from that cultured with DMSO. Meanwhile, the
average length of neurites increased from 206.0 ± 13.1
μm in tumor spheres culture with DMSO to 269.7 ±
28.4 μm in GSI-treated tumor spheres (Figure 5B, 5C).
In order to further confirm whether these cells are the
downstream neural cell types, immunofluorescence was
performed on differentiated primary GSCs using the
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Page 6 of 13Figure 3 Blockade of Notch signaling promotes the differentiation of normal mouse NSCs into INPs and downstream neural cell types.
(A, B) Total RNA was prepared from GSI or DMSO treated neurospheres derived from E12.5 mouse brain on the 5th day of culture. And the
expressions of Glast, Mash1 and Tubulin a1 were measured by RT-PCR (A) and Real-time PCR (B), with b-actin as the reference control (n = 3,
GLAST, P = 0.003, Mash1, P = 0.043, Tubulin a1, P = 0.046). (C, D) Immunofluorescence. Differentiated NSCs were stained with anti-GFAP, or anti-
MAP2 antibodies after cultured on cover slips in differentiation conditional medium for 7 days. Stained samples were examined under a
fluorescence microscope. (E, F) Quantification and comparison of neurons (MAP2
+) or astrocytes (GFAP
+) in GSI-treated and control NSCs. Cells
were counterstained with Hoechst, to permit counting of cell nuclei in at least 5 microscopic fields per specimen (n = 3, E, P = 0.021, F, P =
0.031). *, P < 0.05, **, P < 0.01. Scale bar, 50 μm for C and D.
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day in differentiating conditional medium (Figure 5D,
5E). We quantitatively compared the cell types produced
by neurospheres in the GSI-treated group with that
of the control. The percentages of MAP2
+ cells and
GFAP
+ cells increased significantly, as high as 51.6 ±
6.1% and 44.0 ± 1.7%, respectively (Figure 5F, 5G).
These results suggest that inhibiting Notch signaling
also promotes the differentiation of GSCs.
Blockade of Notch signaling promotes the conversion of
GSCs to INP-like cells
The previous report indicated that blockade of Notch
signaling in the CNS increased the frequency of INPs in
vivo [21]. Precocious differentiation of NSCs into INPs
might exhaust the NSC pool. Therefore, we investigated
the effect of inhibiting Notch signaling on the frequency
of GSCs and INP-like cells in glioma specimen. In an
attempt to distinguish GSCs and INP-like tumor cells,
we examined the expression of several markers that
could distinguish NSCs from INPs by quantitive RT-
PCR [20,21]. Compared with the controls, the primary
tumor spheres in the presence of GSI expressed lower
Glast and CD133, which are indicative of the frequency
of NSCs and GSCs. In contrast, Mash1 was highly
expressed in GSI-treated tumor spheres (Figure 6A, 6B),
although the expression level of another INP marker,
Tubulin a1 was comparable between the GSI-treated
tumor spheres and that of control. Altogether, these
results suggested that blockade of Notch signaling may
Figure 4 Attenuated proliferation and self-renewal ability of patient-derived GSCs on the blockade of Notch signaling. (A, B) Total RNA
was prepared from primary tumor spheres on the 5th day in the presence of GSI or DMSO. And the expressions of Hes5 and Hes1 were
measured by RT-PCR (A) and Real-time PCR (B), with human GAPDH as the reference control (n = 5, Hes5, P = 0.046, Hes1, P = 0.002). (C, D)
Equal number of cells (1 × 10
5/ml) form brain tumor tissues were plated in the growth medium, the number of primary (n = 4, P = 0.008) (C)
and secondary (n = 4, P = 0.041) (D) tumor spheres were counted 7 days after plating. *, P < 0.05, **, P < 0.01.
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Page 8 of 13Figure 5 Augmented neurite outgrowth and enhanced differentiation of patient-derived tumor spheres on the blockade of Notch
signaling. (A) Photomicrographs of differentiated tumor spheres at 72 h after plated in differentiation conditional medium supplemented with
GSI or DMSO. (B, C) Comparison of neurites number (n = 3, P < 0.001) (B) and length (n = 3, P = 0.041) (C) between tumor spheres in the
presence of GSI and DMSO. (D, E) Immunofluorescence. Differentiated tumor spheres were stained with anti-GFAP, or anti-MAP2 antibodies after
cultured on cover slips in differentiation conditional medium for 7 days. Stained samples were examined under a fluorescence microscope. (F, G)
Quantification and comparison of the percentages of neurons (MAP2
+)( n=3 ,P < 0.001) (F) or astrocytes (GFAP
+)( n=3 ,P < 0.001) (G) in the
total cell number revealed by Hoechst counterstaining, between GSI-treated and control GSCs. Scale bar, 100 μm for A, and 50 μm for D and E.
*, P < 0.05, **, P < 0.01.
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cells.
GSCs show resistance to GSI treatment compared with
NSCs
To gain further perspective on the dynamics of cellular
proliferation accompanying differentiation, we treated
NSCs and tumor spheres at a series of time points fol-
lowing GSI treatment with propidium iodide and exam-
ined cell cycle via FACS analysis. Compared with the
controls, nearly 15.5 ± 0.5% of the NSCs treated with
GSI for 24 h are in the G2+M phase, and then sharply
decreased to less than 8.2 ± 1.7% at 72 h (Figure 7A). In
contrast, the ratio of GSCs in the G2+M phase were
slightly elevated at 48 h, and then declined insignifi-
cantly at 72 h (Figure 7B). The result showed that GSI
treatment significantly reduced the ratio of the G2+M
phase NSCs, but there is no obvious effect on the cell
cycle of GSCs. Therefore, NSCs are more sensitive to
GSI, while GSCs display a certain degree of resistance to
GSI at the early stage of the treatment.
Discussion
Tumor stem cells such as GSCs have been considered as a
novel target for the therapy of the malignant tumors,
because these cells are supposed to play an important role
in tumor initiation, growth, and recurrence [4]. Similarities
in the growth characteristics and gene expression patterns
of normal NSCs and GSCs suggest that pathways
Figure 6 GSI-treated primary tumor spheres show similar gene expression profile of INPs. (A, B) cDNA was prepared from total RNA
isolated from primary tumor spheres, treated with GSI or DMSO for 5 days respectively, and the expressions of GLAST (P = 0.002), CD133 (P =
0.015), Mash1 (P = 0.050) and Tubulin a1( P = 0.116), were measured by RT-PCR (A) and Real-time PCR (n = 5) (B), with GAPDH as a reference
control. *, P < 0.05, **, P < 0.01.
Figure 7 Different effects of GSI-treatment on the cell cycle of
NSCs or GSCs. (A, B) Comparisons of cell cycle between NSCs (A)
and GSCs (B) in the presence of GSI or DMSO at 24 h, 48 h, 72 h
using flow cytometry. Data represent as mean ± SD from three
independent experiments. (n = 3, 24 h, P = 0.006, 48 h, P = 0.013).
*, P < 0.05, **, P < 0.01.
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brain tumor stem cells. In the present study, 1) we isolated
GSCs from the human glioma tissues; 2) Like NSCs, these
cells had the ability to form spheres in serum-free medium
supplemented with growth factors and differentiated into
downstream neural cell-like cells; 3) By GSI treatment, the
number of GSCs-derived primary neurospheres and sec-
ondary neurospheres were markedly reduced compared
with those treated with DMSO, indicating that in the long
term culture (7-14 days), the proliferation and self-renewal
ability of GSCs was ultimately reduced, upon the blocking
of Notch signaling; 4) However, within 72 h culture, GSCs
showed a certain degree of GSI-resistance, with undis-
turbed proliferation ability upon GSI treatment; 5) In addi-
tion, we showed that on blocking Notch signaling, GSCs
are much biased to differentiate into INP-like cells, and
ultimately neurons and glial cells in vitro. All these results
suggest a promising preclinical application of Notch sig-
naling antagonist (e.g., GSI)-based CSCs-targeting therapy
in malignant glioma patients.
The frequency of GSCs in tumor tissue
Although CSCs have been identified as an important
factor in tumor initiation and growth, their characteris-
tics remain obscure concerning their heterogeneity.
Here we found in our experiments that although seven
of the nine human gliomas gave rise to proliferating
tumor spheres, different numbers of spheres arisen from
equal primary glioma cells among tumor samples.
It should be noted that the specimens which did not
give rise to proliferating neurospheres were patient
#1 (oligoastrocytoma, gradeII) and #7 (anaplastic astrocy-
toma, grade III), with comparable tumor grades with the
other specimens (Additional file 1: Table S1). Because
samples are usually drawn from the periphery of the
ablated tumor bulk, these two specimens might contain a
certain amount of normal tissues. Overall, equal number
of cells from high-grade and recurrent tumors, such as
giant cell glioblastoma (WHO grade IV) and oligoastrocy-
toma (WHO grade III, recurrent tumor) often generate
more primary tumor spheres. Due to limited number of
samples, our accumulated results could not statistically
lead to the conclusion that high-grade tumors contain
more GSCs at present. However, the tendency described
above indicated that the original frequency of GSCs
might be different among samples according to tumor
grades, or the GSCs from high-grade tumor tissues might
show more typical properties of stem cells with higher
proliferation and self-renewal ability.
INP-like cells in GSCs population
In normal development of the brain, neurons and glia
are generated from both NSCs and more limited INPs.
And blockade of Notch signaling in NSCs have been
shown to promote their conversion into INPs [20,21].
GSCs can differentiate into neurons and astrocytes in
culture medium with serum, as shown by our results
and previous studies [4]. Like INPs, it is possible that an
intermediate glioma progenitor cells (IGPs) also exist,
linking the GSCs-IGPs-Neuron/glia hierarchy in tumor
microenvironment [32]. Our results show that blocking
Notch signaling in the primary tumor spheres leads to
down-regulated mRNA level of CD133, a well accepted
marker of GSCs at present, indicating a decrease of
GSCs. Simultaneously, the mRNA level of Hes5 and
Glast, two markers highly expressed in NSCs were also
decreased, while that of Mash1, a marker up-regulated
in INPs was increased in primary tumor spheres after
being treated with GSI [20]. In addition, Tubulin a1, an
INP marker, seems can not distinguish IGPs from
GSCs. Since GSI-treated primary tumor spheres could
still gave rise to secondary spheres, unless much fewer
than that derived from control primary spheres, the
CD133
low/GLAST
low/Hes5
low/Mash1
high IGPs might
exist, with its number increased and proliferating ability
decreased after the blockade of Notch signaling. There-
fore, inhibiting Notch signaling might have therapeutic
potential for human gliomas by exhausting GSCs and
instruct them into less proliferative IGPs and differen-
tiated neural cell types.
Double positive cell types in the derivatives of GSCs
Although tumor-derived stem cells had many similari-
ties to normal NSCs, it is important to note that differ-
ences might exist between them. Sphere differentiation
assay on the specimen of 4# patient demonstrated that
GSCs could give rise not only to neurons and glia but
also to a few cells that expressed both Map2 and GFAP,
the molecular markers of astrocyte and neuron, respec-
tively (Figure S3). Previous studies have reported similar
abnormal cells in culture derived from pediatric and
adult brain tumors [4,33], indicating that such dual-fate
cells might represent a significant fraction of GSCs
derived progeny. These Map2
+/GFAP
+ cells sometimes
appeared larger than other cells derived from the same
sphere (Figure S3). In addition, the GFAP positive glial
cells derived from GSCs showed abnormal morphology,
with slim cell bodies and neurites, compared with that
derived from NSCs (Figure 3D, Figure 5E). Although
morphological differences might exist between mouse
and human glial cells, previous research on normal
human tissue demonstratedt h a tG F A Ps t a i n i n go f
human glial cells showed similar morphology with that
of mouse glial cells [34]. Therefore, the morphological
difference of GFAP positive glial cells might be attribu-
ted to whether they are NSC-derived or GSC-derived.
Genetically, the generation of the double-positive cells
and dysmorphic glial cells may accompany with gene
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ways, leading to aberrant reprogramming procedure of
GSCs, compared with normal differentiation of NSCs.
GSI-resistance of GSCs at the early stage of GSI treatment
In our study, we found that the numbers of both pri-
mary and secondary tumor spheres were decreased in
the long run (7-day culture) after GSI treatment com-
pared with the controls. However, cell cycle analysis
results showed that although Notch blockade signifi-
cantly reduced the ratio of the G2+M phase in NSCs,
there is no obvious effect on the percentage of prolifer-
ating GSCs within 72 h after GSI treatment. These
results indicate that, compared with NSCs, another dis-
tinctive feature of GSCs was that the former are more
sensitive to GSI, while the latter displays a certain
degree of resistance to GSI treatment at the early stage
of the treatment. Due to the limited amount of primary
glioma specimens, the cell cycle analyses were executed
on primary tumor spheres from three independent
tumor samples. Therefore, the resistance to GSI in
GSCs at the early stage of the cell cycle might be a gen-
eral characteristic in gliomas, or it only represents a few
cases of glioma patients which might display resistance
in the preclinical trial of GSI treatment. Previous
research show that treatment with dipeptide GSI
resulted in a marked reduction in medulloblastoma
growth [35]. More recently, a clinical trial for a Notch
inhibitor, MK0752 (developed by Merck, Whitehouse
Station, NJ), has been launched for T-cell acute lympha-
tic leukemia and breast cancer patients (http://www.clin-
icaltrials.gov/ct/show/NCT00100152). Although GSI
seems to be a promising reagent targeting GSCs by
interfering Notch signaling, our results suggested that
its effect might be limited to some glioma patients.
Therefore, drug combination should be used at the early
stage of therapy. However, since our results are based
on in vitro culture system of patient-derived samples,
more accurate conclusion could be drawn from animal
models or preclinical trials in future study.
The mechanisms of Notch signaling in regulating the
proliferation and differentiation of GSCs
The mechanistic links between Notch signaling and the
proliferation and differentiation of GSCs were presumably
governed by more than one mechanism. In our study, the
decreased proliferation and increased differentiation of
GSCs upon GSI treatment are accompanied with down-
regulation of Hes1 and Hes5, the canonical Notch down-
stream effectors. In addition, the expression level of
Mash1, a proneural gene antagonized by the Hes genes
was up-regulated in GSI-treated primary tumor spheres.
Therefore, the canonical Notch-CBF1-Hes axis seems
also play critical roles in the proliferation and differentia-
tion of GSCs, as its function in NSCs [11].
On the other hand, Notch signaling has been shown
to have both negative and positive influences on cell
cycle progression [11,36]. In the present study, we
observed that the proliferation of GSCs decreased signif-
icantly in the long term culture, although GSI resistance
of three glioma samples was present (see above). Muta-
tions of p53, pTEN and H-Ras, have been identified in
tumor tissues of giloma patients. And Notch signaling
has been shown to crosstalk with p53 and pTEN signal-
ing pathway, two major regulators of cell cycle [37,38].
In addition, down-regulation of Notch signaling in H-
Ras-transformed human breast cells led to a significant
decrease in their proliferation [39]. Therefore, how
Notch signaling promotes the cell cycle of GSCs is yet
to be explored, on the scenery of the complex signal
crosstalk and genetic circuitry.
Conclusion
Our data indicate that like NSCs, Notch signaling maintains
the patient-derived GSCs by promoting their self-renewal
and inhibiting their differentiation, and support that Notch
signal inhibitor might be a prosperous candidate of the
drug treatment targeting CSCs for gliomas, however, with
GSI-resistance at the early stage of treatment.
Additional material
Additional file 1: Hu et al Supplementary materials The file contains
Table S1-S3, Figure S1-S3 and their figure legends
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